Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 11/20 | 0.55 |
| ▸ | ADRB1 | P08588 | 11/20 | 0.55 |
| ▸ | ADRB3 | P13945 | 11/20 | 0.55 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.43 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.43 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.43 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.41 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5443906 | 0.86 | NR1H4 (0.48) | ADRB2ADRB1ADRB3NR1H4 | |
| SCHEMBL5452122 | 0.83 | ADRB2 (0.55) | ADRB2ADRB1ADRB3S1PR1S1PR4 | |
| SCHEMBL5450601 | 0.82 | ADRB2 (0.58) | ADRB2ADRB1ADRB3NR1H4 | |
| SCHEMBL5447417 | 0.81 | ADRB2 (0.55) | ADRB2ADRB1ADRB3SPHK1 | |
| SCHEMBL5448093 | 0.80 | ADRB2 (0.61) | ADRB2ADRB1ADRB3 | |
| SCHEMBL11340641 | 0.79 | S1PR1 (0.60) | S1PR1S1PR4S1PR3S1PR5SPHK1 | |
| SCHEMBL77257 | 0.79 | S1PR1 (0.60) | S1PR1S1PR4S1PR3S1PR5SPHK1 | |
| SCHEMBL5281907 | 0.78 | CYP4F2 (0.52) | ADRB2ADRB1ADRB3S1PR1S1PR4 | |
| SCHEMBL5449569 | 0.78 | IKBKB (0.37) | ADRB2ADRB1ADRB3 | |
| SCHEMBL5447152 | 0.78 | IKBKB (0.37) | ADRB2ADRB1ADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070249630-A1 | Phenethanolamine derivatives for treatment of respiratory diseases | GLAXO GROUP LIMITED (GB) | 2007-10-25 | — | — | US | disclosed |
| US-20050209338-A1 | Phenethanolamine derivatives for treatment of respiratory diseases | GLAXO GROUP LIMITED (GB) | 2005-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209338-A1 | Phenethanolamine derivatives for treatment of respiratory diseases | PHOSPHO1, PNMT, PEBP1 | ADRB2 89/4885ADRB1 192/4885ADRB3 128/4885 |
| US-20070249630-A1 | Phenethanolamine derivatives for treatment of respiratory diseases | PHOSPHO1, PNMT, PEBP1 | ADRB2 89/4885ADRB1 192/4885ADRB3 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.